Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Today's presentation
View:
Post by Melray on May 17, 2022 9:05am

Today's presentation

Best call and presentation in a long time.
Comment by brad129 on May 17, 2022 9:16am
I was thinking the same, had a call come in so I missed a bit, came back and heard no RS in the cards at this time.  
Comment by LithLover on May 17, 2022 9:24am
Aristotle coming to Alberta and Quebec
Comment by Nailbiter1 on May 17, 2022 9:41am
This post has been removed in accordance with Community Policy
Comment by TrippinAgain123 on May 17, 2022 10:30am
This post has been removed in accordance with Community Policy
Comment by Liked2Think on May 17, 2022 11:04am
WAIT! Tripp chuckled a bit? Ok this changes EVERYTHING! Back the money truck up and load up on this stock people!  The CEO had a chuckle! Also after much research it is obivious Quebec has far more patient potential rather than the US or Europe.  Quebec will save the SP!
Comment by thadeush on May 17, 2022 12:55pm
Canada seems similar to the States. If it's doctor-ordered, keep the invoice and see if your insurance carrier will cover it (you can check beforehand, of course). Also sounds like OHIP is ok with it if doctor-ordered. The important thing is they are talking to these people, so the wheels are turning. 
Comment by Nailbiter1 on May 17, 2022 1:34pm
This post has been removed in accordance with Community Policy
Comment by Nailbiter1 on May 17, 2022 2:31pm
This post has been removed in accordance with Community Policy
Comment by IainCaimbeul on May 17, 2022 2:46pm
Always with the arrogance. It's Tripp's job to provide valueable info to the SHAREHOLDERS, some of whom happen to be on this board. Not you or any other pumper. All you add is confusion and biased opinion. P.S it's tatties
Comment by Westcoastrrader on May 18, 2022 12:18am
Under promise over deliver  we have been told so many great potentials in past. Zero have been achieved. Let's see what happens. Track record isn't good  I keep asking myself is if we have the best test on market why aren't sales ramping faster. 
Comment by Melray on May 17, 2022 9:39am
I appreciated the FDA explanation. It makes sense. It's abundantly clear that SZLS is a long term investment with measured growth moving forward. Frankly, that's good and the reason I invested in a cancer detection and care company. Not looking for a roller-coaster quick buck play. Unfortunately, penny stocks come with highwaymen and extreme volatility that tarnish the potential.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities